CA2550155C - Hla-dr-specific antibodies, compositions and methods - Google Patents

Hla-dr-specific antibodies, compositions and methods Download PDF

Info

Publication number
CA2550155C
CA2550155C CA2550155A CA2550155A CA2550155C CA 2550155 C CA2550155 C CA 2550155C CA 2550155 A CA2550155 A CA 2550155A CA 2550155 A CA2550155 A CA 2550155A CA 2550155 C CA2550155 C CA 2550155C
Authority
CA
Canada
Prior art keywords
ser
hla
seq
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2550155A
Other languages
English (en)
French (fr)
Other versions
CA2550155A1 (en
Inventor
Catherine J. Mcmahan
Lara Porter Stepan
Reiner Laus
Damir Vidovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dendreon Pharmaceuticals LLC
Original Assignee
Dendreon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dendreon Corp filed Critical Dendreon Corp
Publication of CA2550155A1 publication Critical patent/CA2550155A1/en
Application granted granted Critical
Publication of CA2550155C publication Critical patent/CA2550155C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2550155A 2003-12-15 2004-12-15 Hla-dr-specific antibodies, compositions and methods Expired - Fee Related CA2550155C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60894403P 2003-12-15 2003-12-15
US60/608,944 2003-12-15
PCT/US2004/042312 WO2005058251A2 (en) 2003-12-15 2004-12-15 Hla-dr-specific antibodies, compositions and methods

Publications (2)

Publication Number Publication Date
CA2550155A1 CA2550155A1 (en) 2005-06-30
CA2550155C true CA2550155C (en) 2015-03-17

Family

ID=34700255

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2550155A Expired - Fee Related CA2550155C (en) 2003-12-15 2004-12-15 Hla-dr-specific antibodies, compositions and methods

Country Status (5)

Country Link
US (1) US8354507B2 (cg-RX-API-DMAC7.html)
EP (1) EP1711527A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007513976A (cg-RX-API-DMAC7.html)
CA (1) CA2550155C (cg-RX-API-DMAC7.html)
WO (1) WO2005058251A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042809A2 (en) * 2005-10-11 2007-04-19 Domantis Limited Antibody polypeptide library screening and selected antibody polypeptides
GB0525214D0 (en) * 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
US9085614B2 (en) * 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
CA3220104A1 (en) * 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
CN104203982B (zh) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
JP2016530244A (ja) * 2013-12-31 2016-09-29 ディベロップメント センター フォー バイオテクノロジーＤｅｖｅｌｏｐｍｅｎｔ Ｃｅｎｔｅｒ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ 抗ｖｅｇｆ抗体及びその使用
CA2987992A1 (en) * 2015-06-04 2016-12-08 University Of Southern California Lym-1 and lym-2 targeted car cell immunotherapy
KR20180087430A (ko) * 2015-12-17 2018-08-01 얀센 바이오테크 인코포레이티드 Hla-dr에 특이적으로 결합하는 항체 및 이의 용도
EP3515491A4 (en) 2016-09-21 2020-09-16 Aptevo Research and Development LLC CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCESSES
EP3515493A4 (en) * 2016-09-23 2020-08-19 University of Southern California CHEMERICAL ANTIGEN RECEPTORS, COORESPONDENT COMPOSITIONS AND METHODS OF USE
JP7280238B2 (ja) * 2017-07-17 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法
SG11202108655TA (en) 2019-02-15 2021-09-29 Univ Southern California Lym-1 and lym-2 antibody compositions and improved car constructs
CN113950483B (zh) * 2019-04-01 2025-08-05 中外制药株式会社 抗hla-dq2.5抗体
CN115028730B (zh) * 2022-05-17 2022-11-08 诺赛联合(北京)生物医学科技有限公司 一种成体干细胞衍生的类器官制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO873164L (no) 1986-07-30 1988-02-01 Teijin Ltd Muse-humane kimaere antistoffer.
JPH0698021B2 (ja) 1986-08-01 1994-12-07 帝人株式会社 マウス−ヒトキメラ抗体、それをコ−ドする発現型キメラｄｎａ配列、プラスミド及び細胞
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
PT877626E (pt) 1996-01-23 2003-01-31 Univ Vermont And State Agric C Anticorpos anti-cd1s para utilizacao contra icto
KR100764256B1 (ko) * 1998-01-23 2007-10-05 에프. 호프만-라 로슈 아게 인간 인터루킨-12에 대한 항체
AU5588099A (en) * 1998-08-28 2000-03-21 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
CN1360596A (zh) * 1999-02-12 2002-07-24 遗传研究所有限公司 与b7分子发生反应的人源化免疫球蛋白及应用该免疫球蛋白的治疗方法
ATE365749T1 (de) 2000-05-12 2007-07-15 Gpc Biotech Ag Humane peptide/proteine, die das töten von zellen,einschliesslich lymphoide tumorzellen, herbeiführen oder bewirken
EP1369431A4 (en) * 2001-10-15 2005-01-12 Kirin Brewery ANTI-HLA-DR ANTIBODIES
JP4723810B2 (ja) * 2001-12-03 2011-07-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド ハイブリッド抗体
US8450348B2 (en) * 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity

Also Published As

Publication number Publication date
WO2005058251A3 (en) 2005-11-17
JP2007513976A (ja) 2007-05-31
US20050208048A1 (en) 2005-09-22
WO2005058251A2 (en) 2005-06-30
CA2550155A1 (en) 2005-06-30
EP1711527A4 (en) 2008-09-03
EP1711527A2 (en) 2006-10-18
US8354507B2 (en) 2013-01-15

Similar Documents

Publication Publication Date Title
CN103687945B (zh) 抗-b7-h3抗体
DK2740744T3 (da) Sp35-antistoffer og anvendelser deraf
EP2516468B1 (en) Anti-flt3 antibodies and methods of using the same
JP6097690B2 (ja) 抗ｃｘｃｌ１３抗体およびそれを用いる方法
US8007798B2 (en) Treatment of complement-associated disorders
JP3611573B2 (ja) モノクローナル抗体の免疫抑制活性および毒性のモジュレーションのための方法ならびに物質
DK2644205T3 (en) Targeting ABCB5 for Cancer Therapy
US7115713B2 (en) Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens
KR20020026542A (ko) 부자극 신호 전달 분자 에이아이엘아이엠에 대한 인간모노클로날 항체 및 그의 약학적 용도
US20150197571A1 (en) Single Agent Anti-PD-L1 and PD-L2 Dual Binding Antibodies and Methods of Use
SG190561A1 (en) Crig polypeptide for prevention and treatment of complement-associated disorders
CA2689680A1 (en) Fc receptor-binding polypeptides with modified effector functions
US7192589B2 (en) Treatment of inflammatory disorders with STIgMA immunoadhesins
KR102862077B1 (ko) 인간화 항-n-절단 아밀로이드 베타 단일 클론 항체
JP2015518857A (ja) Ｉｌ−６結合分子
US8354507B2 (en) HLA-DR specific antibodies, compositions and methods
JPH10257893A (ja) ガングリオシドｇｍ２に対するヒト型相補性決定領域（ｃｄｒ）移植抗体
US11542322B2 (en) Nano-theranostics for Parkinson's disease
JP2024535124A (ja) 破傷風毒素に結合する抗体およびその使用
KR20240047964A (ko) 항-csp 항체
JP2005519590A (ja) 免疫関連疾患の治療のための組成物及び方法
US20260109763A1 (en) Anti-pilra antibodies, uses thereof, and related methods and reagents
US10870694B2 (en) Composition and methods of treating B cell disorders
JP2003524600A (ja) 免疫関連疾患治療のための組成物及び方法
AU778551B2 (en) Novel peptide and screening method by using the same

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20181217